Pathogenesis of Rheumatoid Arthritis. Smolen, J. S. et al. (2012) Nat. Rev. Rheumatol. doi: /nrrheum
|
|
- Megan Higgins
- 5 years ago
- Views:
Transcription
1 1 Pathogenesis of Rheumatoid Arthritis 2 Smolen, J. S. et al. (2012) Nat. Rev. Rheumatol. doi: /nrrheum
2 Biologic therapies used in the treatment of rheumatoid arthritis 3 Etanercept Infliximab Adalimumab Golimumab Certolizumab Woodrick, R. S. & Ruderman, E. M. (2011) Nat. Rev. Rheumatol
3 5 Rheumatoid arthritis Anti-TNF alpha Anti-IL 6 Anti-CTLA4 Anti-CD20 Anti-IL1 JAK inhibitor Ankylosing spondylitis Anti-TNF alpha Psoriasis/psoriatic arthritis Anti-TNF alpha Anti-IL12/23 SLE Anti-BAFF Asthma Anti-IgE Chronic spontaneous urticaria Anti-IgE Inflammatory bowel disease Anti-TNF alpha Biologicals revolutionized rheumatology 6
4 7 But 8 Risk of reactivation of latenttb (high in Mab anti-tnf, intermediate with etanercept) Boyman, O. et al. Nat. Rev. Rheumatol. 10(10), (2014)
5 Risk s Benefits Risk of TB in RA patients 10 Authors, year Locality Comparison group Odds ratio for TB P value or 95% CI Carmona et al., 2003 Askling et al., 2005 Yamada et al., 2006 Seong et al, 2007 Gamboa et al., 2006 Wolfe et al., 2004 Spain population Sweden population Japan population Korea population Peru population (NS) USA population 6.2 vs 5.8/100,000 Not significantly Tam et al., 2010 Hong Kong population
6 BSRBR (UK):Risk of TB with anti-tnf therapy 11 Numbers and rates of incident tuberculosis Rate of TB per 100,000 patient years (no. of cases) DMARD n= (5) ETN n= (11) INF n= (11) ADA n=4857 Adjusted* incidence rate ratios compared to ETN (95% CI) (0.9, 5.8) for INF 4.2 (1.8, 9.9) for ADA Switchers included *adjusted for age, gender and entry year TB, tuberculosis; DMARD, disease modifying anti-rheumatic drugs; CI, confidence interval; TNF, tumor necrosis factor; ETN, etanercept; INF, infliximab; ADA, adalimumab. 1. Dixon W, et al. Ann Rheum Dis 2010;69: RATIO (France): Higher Risk of TB in Both RA and AS Patients Treated With Anti-TNF 12 Cumulative frequency of TB 70% 60% 50% 40% 30% 20% 10% 0% 0 6 Adalimumab Etanercept Time from onset of last TNF-i treatment (months) Total Infliximab The risk of TB is higher for patients receiving anti-tnf mabs than for those receiving soluble receptor TNF-i therapy TB, tuberculosis. Tubach F, et al. Arthritis Rheum. 2009;60: Not a head to head comparison. Differences in baseline characteristics among patient groups may exist 12
7 Higher Incidence of Tuberculosis is Observed in Korean Ankylosing Spondylitis Patients Treated with TNF blockers Incidence Rates of TB in Korea Mean incidence of TB per 100,000 PY AS, ankylosing spondylitis; PY, patient-years; TB, tuberculosis. Adapted from Kim EM, et al. J Rheumatol 2011;38: Biologics Have an Increased Risk of Tuberculosis and Lymphoma Compared to Traditional Diseasemodifying Anti-rheumatic Drugs in Taiwan DMARD vs Biologics in rheumatoid arthritis Traditional DMARDs Biologic DMARDs IRR (95%CI)** Rate/ Rate/ TB *( ) Lymphoma *( ) Serious infection ( ) *P<0.05; **Traditional DMARDs as referent. This data was not adjusted for rheumatoid arthritis disease activity. Not a head-to-head comparison. Differences in baseline characteristics among patient groups may exist. DMARDS, disease-modifying anti-rheumatic drugs; IRR, incidence rate ratio; NNH, number needs to harm; TB, tuberculosis. Adapted from Chiu YM, et al. Int J Rheum Dis 2014;17(Suppl3):9 19.
8 Projected Incremental Tuberculosis Risks in South Asian Countries with TNF inhibitor Therapy Patients (%) Projected incidence of TB on TNF inhibitors in South Asia PHILIPPINES MALAYSIA SINGAPORE THAILAND INDIA VIETNAM NNT (using ETN instead of) Philippines Malaysia Singapore Thailand India Vietnam ADA IFX ADA ETN IFX In South Asia, the estimated number needed to harm is lowest with etanercept Not a head-to-head comparison. Differences in baseline characteristics among patient groups may exist. ADA, adalimumab; ETN, etanercept; IFX, infliximab; NNT, number needed to treat; TB, tuberculosis. Navarra SV, et al. Int J Rheum Dis : Projected Incremental Tuberculosis Risks in North Asian Countries with TNF inhibitor Therapy Patients (%) Projected incidence of TB on TNF inhibitors in North Asia HONG KONG CHINA KOREA MACAU TAIWAN ADA ETN IFX NNT (using ETN instead of) Hong Kong China Korea Macau* Taiwan ADA IFX N/A In North Asia, the estimated number needed to harm is lowest with etanercept Not a head-to-head comparison. Differences in baseline characteristics among patient groups may exist. Infliximab not available in Taiwan. *Macau was not included in the original publication. Data source: ADA, adalimumab; ETN, etanercept; IFX, infliximab; NNT, number needed to treat; TB, tuberculosis. Navarra SV, et al. Int J Rheum Dis :
9 17 Taiwan=49/ WHO Global Tuberculosis Report 2014 ( 10 5 people/year) ( per 10 5 people/year) :
10 Biphasic emergence of active tuberculosis in RA patients receiving TNFα inhibitors Taiwan VGH-TC 19 Chen, DY. et al. Ann Rheum Dis 2012;71: Biphasic emergence of active tuberculosis in RA patients receiving TNFα inhibitors : early TB infection Reactivation 20 Early TB infection No early TB infection Total adalimumab 4 (4.35%) etanercept 0 (0%) Total P=0.023 by Fisher s exact test Data from DY Chen et al. Ann.Rheum.Dis. 71 (2): , 2012
11 Biphasic emergence of active tuberculosis in RA patients receiving TNFα inhibitors : late TB infection New TB infection 21 Late TB infection No TB infection Total adalimumab 2 (2.27%) etanercept 3 (2.13%) Total P=0.656 by Fisher s exact test Data from DY Chen et al. Ann.Rheum.Dis. 71 (2): , 2012 Persistently High Levels of Released IFN-γ or QFT Conversion Strongly Indicate the Development of Active Tuberculosis in Patients Undergoing TNF inhibitor Therapy ESAT-6-stimulated IFNγ release levels (IU/ml) ESAT-6-stimulated IFNγ release levels (IU/ml) *** * * *** Baseline 9 months 18 months 24 months INHP 9 months Anti-TNF treatment TB CFP-10-stimulated IFNγ release levels (IU/ml) TB INHP 2 3 months 0 1 Anti-TNF Rx 3 Anti-TB Rx Anti-TNF Rx Anti-TB Rx 2 6 months Anti-TNF months Anti-TB Rx CFP-10, culture filtrate protein 10; ESAT-6; early secretory antigenic target 6; IFN, interferon; INHP, isoniazid prophylaxis; *P<0.05; **P<0.005; ***P<0.001, versus values at baseline. QFT, QuantiFERON-TB Gold assay; TB, tuberculosis; TST, tuberculin skin test. CFP-10-stimulated IFNγ release levels (IU/ml) Baseline TST+/QFT+ results ESAT-6 CFP-10 ** *** ESAT-6-stimulated IFNγ release levels (IU/ml) ESAT-6-stimulated IFNγ release levels CFP-10-stimulated IFNγ release levels (IU/ml) (IU/ml) Baseline TST /QFT results ESAT-6 CFP-10 Baseline 9 months 18 months24 months 1 TB * TB CFP-10-stimulated IFNγ release levels (IU/ml) Adapted from DY Chen, et al. Ann Rheum Dis 2012;71:
12 How? 23 24
13 25 Mantoux test is a standard method by intra-dermal injection of two tuberculin units of PPD RT-23, and then measurement of induration diameter after 48-72hrs 5 mm 10 mm TST TB 26 Universal use of BCG vaccination (96%) For newborn & 1st degree of elementary school High annual incidence of NTM in Taiwan (21.5/100,000 in 2002) 42% NTM isolation rate in TCVGH The major challenge of TST is the varying and low specificity in various settings, especially in Taiwan
14 A systemic review and meta-analysis showed that TST result is unreliable in BCG-vaccinated people 27 All TST /672 BCG vaccinated /516 Lee et al., 2006 (22) 103/131 Kang et al., 2005 (30) 49/99 Mori et al., 2004 (85) 75/213 Brock et al., 2001 (68) 10/19 Johnson et al., 1999 (69) 53/54 Not BCG vaccinated /156 Taggart et al., 2006 (86) 78/81 Brock et al., 2001 (68) 15/15 Johnson et al., 1999 (69) 60/ Ann Intern Med 2007; (positive TST result was defined as 5mm) 28 Percentage of patients % (RA) 26% (controls) TST(-) 29.4% (RA) 74% (controls) TST(+) >15 PPD value (mm) RA Controls 25 Ponce de Leon, D et al. Ann Rheum Dis 2005;64:
15 Anti-TNF trial for Taiwanese patients with RA in RA Patients N= 43 Baseline screening: risk factor survey, history of TB exposure, CXR TST Positive N=8 (18.6%) INH Prophylaxis for 9 months TST Negative N=35 (81.4%) No TB (0%) No hepatotoxicity/allergy Active TB infection N= 2 No TB N= % RA patients had TST-positive results at baseline (BCG vaccination +) before anti-tnf therapy in Taiwan (One-step TST test) Chen DY et al. Arthritis & Rheumatism (Arthritis Care & Research) 59(6) :For 132 Taiwanese patients with RA before anti-tnf Rx. Two-step TST could increase positive rate (cutoff 5 mm) by 19.1% 30 Negative Positive 1st TST 101/ % 31/ % 2 step TST 75/132 57/ % within 1-5 wks after 1 st TST 56.8% 43.2% Our results could be explained by Booster phenomenon that was also noted in 29% of RA patients (J Rheumatol 2007;34:474)
16 Summary : TST screening in RA 31 Anergy [false (-) TST] is common in RA patients The use of immunosuppressive agents Immune dysfunction related to RA Two-step TST is necessary in the detection of LTBI for RA patients before starting anti-tnf therapy The application of TST for detecting LTBI is limited in RA patients by the frequent presence of anergy 32 4/43=9302/10 5 Chen DY et al. Arthritis & Rheumatism (Arthritis Care & Research) 59(6)
17 Combined QFT-G assay and TST can aid in detecting LTBI in RA patients receiving adalimumab therapy TST? The application of TST for detecting LTBI is limited in RA patients by the frequent presence of anergy 33 Chen DY et al. Arthritis & Rheumatism 59(6) 2008, Screening protocol for RA patients receiving TNFα inhibitors at VGH-TC Taiwan Chen, DY. et al. Ann Rheum Dis 2012;71:
18 35 Chen, DY. et al. Ann Rheum Dis 2012;71: Biphasic emergence of active tuberculosis in RA patients receiving TNFα inhibitors Taiwan VGH-TC 36 Chen, DY. et al. Ann Rheum Dis 2012;71:
19 In vitro IFN-γ release assays (QFT, T-spot) 37 ESAT-6,CFP-10, TB7.7 (BCG ) ELISA IFN-γ IFN-γ QFT assay has higher specificity (96%) vs. TST in BCG-vaccinated people 38 Sensitivity Specificity TST QFT Ann Intern Med 2008;149:177-84
20 Persistently high levels of released IFN-γ or QFT-G conversion strongly indicate the development of active TB in patients undergoing anti-tnf Rx Taiwan VGH-TC 39 DY Chen et al. Ann.Rheum.Dis. 71 (2): , 2012 DY Chen et al. Ann.Rheum.Dis. 71 (2): , RA patients scheduled for anti-tnf Rx (n=242) Screening of LTBI: TST and QFT assay 40 9 patients excluded due to indeterminate QFT TST+ / QFT+ (n=37) TST+ / QFT - (n=38) TST- / QFT + (n=8) TST- / QFT- (n=150) TST 10 mm (n=24) TST 5-9 mm (n=14) INAH 1 mon before anti-tnf Rx INHP + Anti-TNF Rx Anti-TNF Rx TB (n=2) Rising IFN-γ levels in QFT Continue anti-tnf x 9 mons Decrease IFN-γ levels TB x1 Rising IFN-γ Continue anti-tnf Repeat QFT (-) TB x1 QFT conversion Anti-TB Rx Continue anti-tnf Rx x 15 mon (n=73) Anti-TB Rx Continue anti-tnf Rx x 15 mon (n=156) Anti-TB Rx TB (-) Decrease IFN-γ levels TB (-) x 7 QFT reversion TB (-) x 144 Repeat QFT(-) TB (n=5) QFT conversion
21 41 DY Chen et al. Ann.Rheum.Dis. 71 (2): , step TST (-) (induration diameter < 5mm) 2-step TST (+) (induration 5mm) IGRAs (+) (QFT or T-Spot) 1.Prophylactic Rx 2.Close monitor* 1.Prophylactic Rx 2.Consult TB specialist 3. Close monitor* IGRAs (-) (QFT or T-Spot) 1.Start Biologics 2.Periodic CXR/IGRAs 1.Prophylactic Rx (TST > 10 mm) 2.Close monitor* Baseline IGRAs Indeterminate 1 IGRAs * TB Close monitor: CXR IGRAs Formosian Journal of Rheumatology 2011;25,6-10
22 TRA Recommendation Formosan Journal of Rheumatology 26(1) 8~14, 2012
23 RA ( 10 ) RMP RMP RMP RA TB * # # 46 * Hsueh PR. et al. J Infect 2006;52: # Ke WM. et al. Int J Tuberc Lung Dis. 2013;17:
24 47 Navarra SV et al. Int J Rheum Dis. 2014;17: Risk of TB reactivation in Spain IRR vs. general Population IRR vs. RA with csdmards Before RMP After RMP % compliance 1.8 Undetermined < 100% compliance Gomez-Reino JJ et al. Arthritis Rheum 2007;57:
25 Reasons of decreased TB incidence in patients using biologics Increased awareness Screening for latent TB Treatment for latent TB Introduction of lower TB risk drugs Arkema EV, et al. Ann Rheum Dis 2015;74: About QuantiFERON-TB test
26 easy steps of QFT In-Tube 51 Indeterminate rates in immune suppressed and immunocompetent populations 52 Population QFT T-SPOT.TB Pearson Chi-Square No. No. % No. No. % (QFT vs T-SPOT.TB) Tested Indet* Indet* Tested Indet* Indet* Overall 17, % 13, % p< Immunosuppressed Immunocompetent 12, %10, % p< , % 2, % p<0.0001
27 QFT indeterminate data 53 Lab A-1* Lab A-2** Lab B Lab C Lab D-1*** Lab D-2* Test numbers Positive N/A 224 N/A N/A N/A N/A Negative N/A 373 N/A N/A N/A N/A Indeterminate 9 (3.7%) 4 (0.67%) 28 (6.8%) 45 (15.68%) 34 (5.52%) 3 (7.7%) * (< 4.42%) ** *** (< 2.14%) 54
28 55 QFT reproducibility within 10 weeks Consistent results: 72.67% Weakly positive results A. Felber, W. Graninger. Tuberculosis 2013:93; 647e653
29 Low titer = frequent conversion? 80% of all subjects with discordant results within 10 weeks had low positive IFN-γ-responses. (mean 0.75 vs IU/ml of persistent positive patients) A low IFN- γ level may alternatively be considered as false positive, especially in those exhibiting NO clinical features or risk factors of TB. A. Felber, W. Graninger. Tuberculosis 2013:93; 647e653 Hong Kong Biologics Registry: Tuberculosis and Non-tuberculosis Serious Infections Event rate of TB (per 100 patient-years) IFX ETN ADA GLM TCZ RTX Total Event rate of Serious/recurrent infections (non-tb) (per 100 patient-years) IFX ETN ADA GLM TCZ RTX Total Events IFX ETN ADA GLM TCZ RTX Total Tuberculosis Serious/recurrent infections (non-tb) Skin rash/allergy Not a head-to-head comparison. Differences in baseline characteristics among patient groups may exist. ADA, adalimumab; ETN, etanercept; GLM, golimumab; IFX, infliximab; RTX, rituximab; TB, tuberculosis; TCZ, tocilizumab. Adapted from Mok CC, et al. Int J Rheum Dis 2014;17Suppl 3:1 8.
30 2015 TRA Recommendation for TB Screening/management before biologics Chen,YH et al. Formosan Journal of Rheumatology 29(1) 1-8 Host-related TB risk factors except rheumatic disease 2015 revised TRA Recommendation per se Chen,YH et al. Formosan Journal of Rheumatology ;29(1),1-8
31 Traditional chemical DMARD-related TB risk factors except rheumatic disease per se 2015 revised TRA Recommendation Risk estimated relative risk (RR) Major risk factors (RR>10) leflumomide 11.7 Minor risk factors (RR<10) cyclosporine 3.8 methotrexate 3.4 corticosteroids 2.4 other (sulfasalazine, azathiorpine, hydroxychloquine) 1.6 Chen,YH et al. Formosan Journal of Rheumatology;29(1),1-8 Risk for TB reactivation among different biologics by meta-analysis Biologics 2015 revised TRA Recommendation LTE studies[44] IR(95%CI) 2013 Cochrane review[19] Odds ratio (95% CI) Cetrolizumab Infliximab Adalimumab Golimumab Tocilizumab Etanercept Abatacept ( ) ( ) ( ) ( ) ( ) ( ) ( ) 4.43( ) 2.82( ) 2.14( ) 3.04( ) Not estimable 1.48( ) 0.50( ) Rituximab 20( ) --- LTE: long-term extension; IR:incidence rate per 100,000 patient-years CI: confidence interval Chen,YH et al. Formosan Journal of Rheumatology ;29(1),1-8
32 2015 TRA Recommendation for TB Screening/management before biologics a.inah 300mg QD x 9M b.inah 300mg QD+rifampin 10mg/kg/day x 3 M c.inah 900mg + rifampentine 900mg QW x 3M d. rifampin 10mg/kg/day x 4M Chen,YH et al. Formosan Journal of Rheumatology 29(1) 1-8 Take Home Message 64
33 Thank you 65
Tuberculosis and Biologic Therapies: Risk and Prevention
Tuberculosis and Biologic Therapies: Risk and Prevention Kevin L. Winthrop, MD, MPH Associate Professor, Divisions of Infectious Diseases, Public Health and Preventive Medicine Oregon Health & Science
More informationTB Prevention Who and How to Screen
TB Prevention Who and How to Screen 4.8.07. IUATLD 1st Asia Pacific Region Conference 2007 Dr Cynthia Chee Dept of Respiratory Medicine / TB Control Unit Tan Tock Seng Hospital, Singapore Cycle of Infection
More informationTuberculosis and TNF Inhibitors
Tuberculosis and TNF Inhibitors Sundari Mase MD, MPH Medical Team Lead CDC/DTBE/FSEB January 18, 2011 Objectives Discuss the association between and epidemiology of TNF inhibitors and TB Discuss the challenges
More information(2) 83.3% b/w TST and T-SPOT, (2) 77.4% b/w TST and T-SPOT. 77.7% b/w TST and QFT-GIT. QFT-GIT, 22.2% in T-SPOT. TSPOT vs. TST (> 5 mm) vs.
Supplementary Table 1. Study characteristics of the included literature Low to moderate TB endemic region Shovman et al. (2009) [21] Minguez et al. (2012) [16], type 35 RA 35 RA 53 Patients with s (RA
More informationESCMID Online Lecture Library. by author
Tuberculosis prevention in immunodepressed patients M. Carmen Fariñas Álvarez Infectious Diseases.H.U.Marqués de Valdecilla University of Cantabria, Spain DISCLOSURES I have no potential conflicts with
More informationApproaches to LTBI Diagnosis
Approaches to LTBI Diagnosis Focus on LTBI October 8 th, 2018 Michelle Haas, M.D. Associate Director Denver Metro Tuberculosis Program Denver Public Health DISCLOSURES I have no disclosures or conflicts
More informationTB Intensive Tyler, Texas December 2-4, 2008
TB Intensive Tyler, Texas December 2-4, 2008 Interferon Gamma Releasing Assays: Diagnosing TB in the 21 st Century Peter Barnes, MD December 2, 2008 TOPICS Use of interferon-gamma release assays (IGRAs)
More informationTargeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection (LTBI) Lloyd Friedman, M.D. Milford Hospital Yale University
Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection (LTBI) Lloyd Friedman, M.D. Milford Hospital Yale University Tuberculosis Estimates USA World Infection 15,000,000 2,000,000,000
More informationEvaluation and Treatment of TB Contacts Tyler, Texas April 11, 2014
Evaluation and Treatment of TB Contacts Tyler, Texas April 11, 2014 Interferon Gamma Release Assays: Understanding the Test David Griffith, BA, MD April 11, 2014 David Griffith, BA, MD has the following
More informationIdentification of latent tuberculosis infection in rheumatic patients under consideration for treatment with anti-tnf-α agents
Clinical research Identification of latent tuberculosis infection in rheumatic patients under consideration for treatment with anti-tnf-α agents Jolanta Paluch-Oleś 1, Agnieszka Magryś 1, Maria Kozioł-Montewka
More informationTUBERCULOSIS AND THE TNF-α INHIBITORS. Lloyd Friedman, M.D. Yale University Milford Hospital
TUBERCULOSIS AND THE TNF-α INHIBITORS Lloyd Friedman, M.D. Yale University Milford Hospital Outline TNF-α Anti-TNF-α medications Rates of tuberculosis Lower rates with etanercept Screening for latent tuberculosis
More informationTB Intensive Houston, Texas October 15-17, 2013
TB Intensive Houston, Texas October 15-17, 2013 Interferon Gamma Release Assays (IGRA s) Lisa Armitige, MD, PhD October 16, 2013 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict
More informationEvidence-based use of the new diagnostic tools for TB-infection
Evidence-based use of the new diagnostic tools for TB-infection Roland Diel, MD, MPH German Central Committee against Tuberculosis, Germany 20. Tuberkulose-Symposium in Münchenwiler, 24 th March 2011 1
More informationTB Nurse Case Management San Antonio, Texas July 18 20, 2012
TB Nurse Case Management San Antonio, Texas July 18 20, 2012 IGRA s and Their Use in TB Nurse NCM Lisa Armitige, MD, PhD July 18, 2012 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict
More informationTB Intensive San Antonio, Texas November 11 14, 2014
TB Intensive San Antonio, Texas November 11 14, 2014 Interferon Gamma Release Assays Lisa Armitige, MD, PhD November 12, 2014 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of
More informationTuberculosis Update. Topics to be Addressed
Tuberculosis Update Robert M. Jasmer, M.D. University of California, San Francisco TB Control Section, San Francisco Department of Public Health Topics to be Addressed TB in the USA Screening recommendations
More informationLTBI Treatment and Anti TNF alpha
LTBI Treatment and Anti TNF alpha Therapy Julie Higashi, MD PhD Director, TB Control Section San Francisco Department of Public Health TNF alpha is important for the immune response against TB Macrophages
More informationDENOMINATOR: All patients aged 18 and older with a diagnosis of inflammatory bowel disease
Measure #274: Inflammatory Bowel Disease (IBD): Testing for Latent Tuberculosis (TB) Before Initiating Anti-TNF (Tumor Necrosis Factor) Therapy National Quality Strategy Domain: Effective Clinical Care
More informationMycobacterial Infections: What the Primary Provider Should Know about Tuberculosis
Mycobacterial Infections: What the Primary Provider Should Know about Tuberculosis Henry F. Chambers, M.D Professor of Medicine, UCSF Topics for Discussion Epidemiology Diagnosis of active TB Screening
More informationTuberculosis in Non-HIV Infected Immunosuppresed Hosts. TNFα inhibitors and beyond
Tuberculosis in Non-HIV Infected Immunosuppresed Hosts TNFα inhibitors and beyond David E. Griffith, MD Assistant Medical Director Heartland National TB Center Professor of Medicine University of Texas
More informationCHILDHOOD TUBERCULOSIS: NEW WRINKLES IN AN OLD DISEASE [FOR THE NON-TB EXPERT]
CHILDHOOD TUBERCULOSIS: NEW WRINKLES IN AN OLD DISEASE [FOR THE NON-TB EXPERT] QUESTION: : Which children in the United States should get a tuberculin skin test? Do questionnaires really work? Jeffrey
More informationUsing Interferon Gamma Release Assays for Diagnosis of TB Infection
Learning Objectives Using Interferon Gamma Release Assays for Diagnosis of TB Infection 1. Describe available Interferon Gamma Release Assay tests for TB infection and how they work. 2. Understand interpretation
More informationInfections and Biologics
Overview Infections and Biologics James Galloway What is the risk of infection with biologics? Are some patients at greater risk? Are some drugs safer? Case scenario You recently commenced Judith, a 54
More informationBarbara J Seaworth MD Medical Director, Heartland National TB Center Professor, Internal Medicine and Infectious Disease UT Health Northeast
Practical Aspects for Using the Interferon Gamma Release Assay (IGRA) Test Live Webinar July 14, 2017 Barbara J Seaworth MD Medical Director, Heartland National TB Center Professor, Internal Medicine and
More informationDimitrios Vassilopoulos,* Stamatoula Tsikrika, Chrisoula Hatzara, Varvara Podia, Anna Kandili, Nikolaos Stamoulis, and Emilia Hadziyannis
CLINICAL AND VACCINE IMMUNOLOGY, Dec. 2011, p. 2102 2108 Vol. 18, No. 12 1556-6811/11/$12.00 doi:10.1128/cvi.05299-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Comparison
More informationA Clinician s Perspective: Improving Rheumatology Patient Care Using the T-SPOT.TB Test
A Clinician s Perspective: Improving Rheumatology Patient Care Using the T-SPOT.TB Test Solomon Forouzesh, MD, FACD, FACR Medical Director Arthritis Care & Treatment Center Clinical Associate Professor
More informationLatent TB Infection (LTBI)
Latent TB Infection (LTBI) Diagnosis & Treatment of Latent TB Infection (LTBI) Amee Patrawalla MD MPH Assistant Professor UMDNJ-New Jersey Medical School Infection with Mycobacterium tuberculosis without
More informationDiagnosis Latent Tuberculosis. Disclosures. Case
Diagnosis Latent Tuberculosis Neha Shah MD MPH Field Medical Officer Tuberculosis Control Branch California Department of Public Health Centers for Disease Control and Prevention September 2016 1 Disclosures
More informationLet s Talk TB A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year
A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year Madhukar Pai, MD, PhD Author and Series Editor Camilla Rodrigues, MD co-author Abstract Most individuals who get exposed
More informationTechnical Bulletin No. 172
CPAL Central Pennsylvania Alliance Laboratory QuantiFERON -TB Gold Plus Assay Contact: J Matthew Groeller, MPA(HCM), MT(ASCP), 717-851-4516 Operations Manager, Clinical Pathology, CPAL Jennifer Thebo,
More informationLATENT TUBERCULOSIS. Robert F. Tyree, MD
LATENT TUBERCULOSIS Robert F. Tyree, MD 1 YK TB OFFICERS Ron Bowerman Elizabeth Roll Mien Chyi (Pediatrics) Cindi Mondesir (Pediatrics) The new guys: Philip Johnson Robert Tyree 2009 CDC TB CASE DEFINITION
More informationDidactic Series. Latent TB Infection in HIV Infection
Didactic Series Latent TB Infection in HIV Infection Jacqueline Peterson Tulsky, MD UCSF Positive Health Program at SFGH Medical Director, SF and North Coast AETC March 13, 2014 ACCREDITATION STATEMENT:
More informationScreening for Tuberculosis Infection. Harlingen, TX. Linda Dooley, MD has the following disclosures to make:
TB Infection Diagnosis Recommendations Talk Developed by Lisa Y. Armitige, MD, PhD Medical Consultant, Heartland National TB Center Associate Professor Internal Medicine/Pediatrics/Infectious Disease UT
More informationPREVENTION OF TUBERCULOSIS. Dr Amitesh Aggarwal
PREVENTION OF TUBERCULOSIS Dr Amitesh Aggarwal 25 to 50 % of persons exposed to intimate contact with active PTB - latent infection with TB. Exposure to index case for 12 hours - high risk of infection.
More informationPredictive values of IGRAs and TST for progression to active disease in TB. 3 rd Global IGRA Symposium January 2012.
Predictive values of IGRAs and for progression to active disease in TB contacts in Singapore Cynthia B E Chee 1, K W KhinMar 1, S H Gan 1, J Cutter, T M Barkham, Y T Wang 1 1 TB Control Unit, Tan Tock
More informationPeggy Leslie-Smith, RN
Peggy Leslie-Smith, RN EMPLOYEE HEALTH DIRECTOR - AVERA TRAINING CONTENT 1. South Dakota Regulations 2. Iowa Regulations 3. Minnesota Regulations 4. Interferon Gamma Release Assay (IGRA)Testing 1 SOUTH
More informationThe Origin of Swine Flu
How the Heck Do You Diagnose Tuberculosis in Children, Anyway? Jeffrey R. Starke, M.D. Professor and Vice Chairman of Pediatrics Baylor College of Medicine Houston, Texas USA The Origin of Swine Flu MAIN
More informationLatent Tuberculosis Infection Controversies in Diagnosis and Management of LTBI
Latent Tuberculosis Infection Controversies in Diagnosis and Management of LTBI Gregory J. Martin MD Tropical Medicine - Infectious Diseases Office of Medical Services Washington, DC 1 The opinions expressed
More informationIdentifying TB co-infection : new approaches?
Identifying TB co-infection : new approaches? Charoen Chuchottaworn MD. Senior Medical Advisor, Central Chest Institute of Thailand, Department of Medical Services, MoPH Primary tuberculosis Natural history
More informationTuberculin Skin Test (TST) and Interferon-gamma Release Assays (IGRA)
Tuberculin Skin Test (TST) and Interferon-gamma Release Assays (IGRA) April 2018 Bob Belknap M.D. Director, Denver Metro TB Program No Disclosures Objectives be able to describe: 1. Who should get tested
More informationEffect of prolonged incubation time on the results of the QuantiFERON TB Gold In-Tube assay for the diagnosis of latent tuberculosis infection
CVI Accepts, published online ahead of print on 3 July 2013 Clin. Vaccine Immunol. doi:10.1128/cvi.00290-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. 1 2 3 Effect of prolonged
More informationUpdate on IGRA Predictive Value
Update on IGRA Predictive Value Sandra Kik, PhD Molebogeng Rangaka, MD, PhD Madhukar Pai, MD, PhD McGill International TB Centre, McGill University University of Cape Town & London School of Hygiene and
More informationA look at medical factors that increase the risk for TB disease
A look at medical factors that increase the risk for TB disease Mark Lobato, MD New England TB Consultant Division of Tuberculosis Elimination CDC Overview The spectrum of M. tuberculosis infection Immune
More informationMaking the Diagnosis of Tuberculosis
Making the Diagnosis of Tuberculosis Alfred Lardizabal, MD NJMS Global Tuberculosis Institute Testing for TB Infection Targeted Testing: Key Points Test only if plan for ensuring treatment De-emphasizes
More informationOriginal article RHEUMATOLOGY
RHEUMATOLOGY Rheumatology 2013;52:697 704 doi:10.1093/rheumatology/kes365 Advance Access publication 22 December 2012 Original article The effects of rituximab therapy on released interferon-c levels in
More informationDiagnosis & Management of Latent TB Infection
Diagnosis & Management of Latent TB Infection Prof. Ashok Rattan, MD, MAMS, INSA DFG, WHO Lab Director Academics, Industry: Research, Diagnosis, Public Health, Academics Adviser: Laboratory Operations,
More informationBIOLOGICS AND RISK OF MALIGNANCIES: SCREENING PROCEDURES AND PATIENT FOLLOW UP
BIOLOGICS AND RISK OF MALIGNANCIES: SCREENING PROCEDURES AND PATIENT FOLLOW UP Dott. Fabrizio Cantini U.O. Medicina II-Reumatologia Ospedale di Prato CURRENTLY EMPLOYED AND COMING UP BIOLOGICS CURRENT
More informationDiagnosis and Medical Case Management of Latent TB. Bryan Rock, MD April 27, 2010
TB Nurse Case Management Lisle, Illinois April 27-28, 28 2010 Diagnosis and Medical Case Management of Latent TB Infection Bryan Rock, MD April 27, 2010 DIAGNOSIS AND MANAGEMENT OF LATENT TUBERCULOSIS
More informationTB testing in children on biologics
TB testing in children on biologics Version: 1 Approval Committee: Date of Approval: Ratification Group (eg Clinical network): Date of Ratification Signature of ratifying Group Chair Author(s) and title
More informationCimzia. Cimzia (certolizumab pegol) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.11 Section: Prescription Drugs Effective Date: April 1, 2018 Subject: Cimzia Page: 1 of 5 Last Review
More informationTB Intensive San Antonio, Texas
TB Intensive San Antonio, Texas August 2, 2011 ATS/CDC Guidelines for Treating LTBI Timothy Aksamit, MD April 6, 2011 Timothy Aksamit, MD has the following disclosures to make: No conflict of interests
More informationTargeted Testing and the Diagnosis of. Latent Tuberculosis. Infection and Tuberculosis Disease
Self-Study Study Modules on Tuberculosis Targeted Testing and the Diagnosis of Latent Tuberculosis Infection and Tuberculosis Disease 1 Module 3: Objectives At completion of this module, learners will
More informationATS/CDC Guidelines for Treating Latent TB Infection
TB Intensive Tyler, Texas June 2-4, 2010 ATS/CDC Guidelines for Treating Latent TB Infection Timothy R. Aksamit, MD June 2, 2010 ATS/CDC Guidelines for Treating LTBI Tuberculosis Intensive University of
More informationTB Intensive San Antonio, Texas
TB Intensive San Antonio, Texas August 2-5, 2011 Pediatric TB Jeffrey Starke, MD August 5, 2011 Jeffrey Starke, MD has the following disclosures to make: Is on a data safety monitoring board for Hoffman
More informationLatent Tuberculosis Best Practices
Latent Tuberculosis Best Practices Last Updated September 7, 2016 LTBI Demographics in the US o 13million people in the US with LTBI (estimate) o In 2014, approximately 66% of TB cases in the United States
More informationKJLM. Serial Interferon-gamma Release Assays for the Diagnosis of Latent Tuberculosis Infection in Patients Treated with Immunosuppressive Agents
Korean J Lab Med 2011;31:271-278 Original Article Diagnostic Immunology KJLM Serial Interferon-gamma Release Assays for the Diagnosis of Latent Tuberculosis Infection in Patients Treated with Immunosuppressive
More informationTB, BCG and other things. Chris Conlon Infectious Diseases Oxford
TB, BCG and other things Chris Conlon Infectious Diseases Oxford Epidemiology Latent TB IGRA BCG >50/100000
More informationTNF-alpha antagonist therapy modify the tuberculin skin test response
DOI 10.1007/s00296-010-1424-3 ORIGINAL ARTICLE TNF-alpha antagonist therapy modify the tuberculin skin test response Tulin Cagatay Zeki Kilicaslan Penbe Cagatay Munevver Mertsoylu Ziya Gulbaran Reyhan
More informationEvaluation and Management of the Patient with Latent Tuberculosis Infection (LTBI)
Evaluation and Management of the Patient with Latent Tuberculosis Infection (LTBI) CURTIS FOWLER MPT,PA C ASSISTANT CLINICAL PROFESSOR UNIVERSITY OF THE PACIFIC Learning objectives Recognize the appropriate
More informationDetecting latent tuberculosis using interferon gamma release assays (IGRA)
Detecting latent tuberculosis using interferon gamma release assays (IGRA) American Society for Microbiology June 2017 Edward Desmond, Ph.D., D (ABMM) San Lorenzo, CA Edward Desmond has no financial connections
More informationTesting & Treatment for TB Infection: Blood Tests, Skin Tests, Who to Screen & Who to Treat?
NECHA 11/4/2016 Testing & Treatment for TB Infection: Blood Tests, Skin Tests, Who to Screen & Who to Treat? E. Jane Carter, M.D. Immediate Past President International Union Against TB and Lung Disease
More informationUtility of PPD or IGRA to answer the age old question of "TB or not TB
Utility of PPD or IGRA to answer the age old question of "TB or not TB Thomas S. Alexander, Ph.D., D(ABMLI) Immunologist Summa Health alexandt@summahealth.org Yes, The reservation is in the name of Dr.
More informationSystematic review: agreement between the latent tuberculosis screening tests among patients with rheumatic diseases
ORIGINAL ARTICLE Korean J Intern Med 2018;33:1241-1251 Systematic review: agreement between the latent tuberculosis screening tests among with diseases Junhee Pyo 1, Soo-Kyung Cho 2, Dam Kim 2, and Yoon-Kyoung
More informationRegulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.51 Subject: Simponi / Simponi ARIA Page: 1 of 9 Last Review Date: March 16, 2018 Simponi / Simponi
More informationDetecting latent tuberculosis infection during anti-tumour necrosis factor therapy
Detecting latent tuberculosis infection during anti-tumour necrosis factor therapy J.S. Ringrose 1, S.E. Sanche 2, R.M. Taylor-Gjevre 3 1 Division of General Internal Medicine, Department of Medicine,
More informationSkin cancers in patients treated with immunomodulating drugs. Manuelle Viguier, MD, PhD Dermatology department Saint-Louis Hospital Paris, France
Skin cancers in patients treated with immunomodulating drugs Manuelle Viguier, MD, PhD Dermatology department Saint-Louis Hospital Paris, France Immunomodulating drugs used in Methotrexate Mycophenolate
More informationORIGINAL ARTICLE Immunology, Allergic Disorders & Rheumatology INTRODUCTION MATERIALS AND METHODS
ORIGINAL ARTICLE Immunology, Allergic Disorders & Rheumatology http://dx.doi.org/10.3346/jkms.2014.29.1.38 J Korean Med Sci 2014; 29: 38-42 Safe Re-administration of Tumor Necrosis Factor-alpha (TNFα)
More informationCimzia. Cimzia (certolizumab pegol) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.11 Subject: Cimzia Page: 1 of 5 Last Review Date: December 8, 2017 Cimzia Description Cimzia (certolizumab
More informationTB Intensive. San San Antonio, Texas. December 1-3, 2010
TB Intensive San Antonio, Texas December 1-3, 2010 ATS/CDC Guidelines for Treating Latent TB Infection Timothy Aksamit, MD; Mayo Clinic December 1, 2010 ATS/CDC Guidelines for Treating LTBI Tuberculosis
More informationTB Intensive San Antonio, Texas August 7-10, 2012
TB Intensive San Antonio, Texas August 7-10, 2012 ATS/CDC Guidelines for Treating Latent TB Infection Timothy Aksamit, MD August 7, 2012 Timothy Aksamit, MD has the following disclosures to make: No conflict
More informationCategory Description / Key Findings Publication
PUBLICATIONS Selected T-SPOT.TB test publications, by area of interest, up to 31 th August 2016. Category Description / Key Findings Publication Background A useful primer on the evolution, administration
More informationAuthor's response to reviews
Author's response to reviews Title: Contribution of Interferon Gamma Release Assays testing to the Diagnosis of Latent Tuberculosis Infection in HIV-Infected Patients: A comparison of QuantiFERON Gold
More informationDiagnosis and Management of Latent TB Infection Douglas Hornick, MD September 27, 2011
TB Nurse Case Management Davenport, Iowa September 27 28, 2011 Diagnosis and Management of Latent TB Infection Douglas Hornick, MD September 27, 2011 Douglas Hornick, MD has the following disclosures to
More informationTuberculin Skin Test (TST) and Interferon-gamma Release Assays (IGRA)
Tuberculin Skin Test (TST) and Interferon-gamma Release Assays (IGRA) April 2019 Bob Belknap M.D. Director, Denver Metro TB Program Disclosures No relevant financial relationships Objectives Be able to
More informationCimzia. Cimzia (certolizumab pegol) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Cimzia Page: 1 of 5 Last Review Date: March 17, 2017 Cimzia Description Cimzia (certolizumab pegol)
More informationTB Skin Test Practicum Houston, Texas Region 6/5 South September 23, 2014
TB Skin Test Practicum Houston, Texas Region 6/5 South September 23, 2014 Catalina Navarro, BSN, RN has the following disclosures to make: No conflict of interests No relevant financial relationships with
More informationESCMID Online Lecture Library. by author
Therapies or diseases predisposing to infection Congenital immunodeficiences Acquired conditions Common variable immunedeficiency particular diseases (e.g. HIV, cancer,leukemia, lymphoma, diabetes, cystic
More informationLATENT TUBERCULOSIS SCREENING AND TREATMENT:
LATENT TUBERCULOSIS SCREENING AND TREATMENT: TB or not TB Christopher Kwong, MD and William Rifkin, MD Week 14 Educational Objectives: 1. Understand who should be screened for latent TB infection and why
More informationScreening and management of latent TB Infection Gerry Davies
Screening and management of latent TB Infection Gerry Davies Reader in Infection Pharmacology Institutes of Infection and Global Health & Translational Medicine HIV Scientific Meeting Liverpool 21st July
More informationORIGINAL ARTICLE. Clinical evaluation of QuantiFERON TB-2G test for immunocompromised patients
ERJ Express. Published on July 25, 2007 as doi: 10.1183/09031936.00040007 ORIGINAL ARTICLE Clinical evaluation of QuantiFERON TB-2G test for immunocompromised patients Yoshihiro Kobashi, Keiji Mouri, Yasushi
More informationLatent tuberculosis (TB) infection (LTBI), a
COMMENTARY Time for a change? Updated guidelines using interferon gamma release assays for detection of latent tuberculosis infection in the office setting Marisa Kardos, BS, and Alexa Boer Kimball, MD,
More informationLatent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016
Latent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016 Randy Culpepper, MD, MPH Deputy Heath Officer/Medical Director Frederick County Health Department March 16, 2016 2 No
More informationTuberculosis Tools: A Clinical Update
Tuberculosis Tools: A Clinical Update CAPA Conference 2014 JoAnn Deasy, PA-C. MPH, DFAAPA jadeasy@sbcglobal.net Adjunct Faculty Touro PA Program Learning Objectives Outline the pathogenesis of active pulmonary
More informationSelf-Study Modules on Tuberculosis
Self-Study Modules on Tuberculosis Targe te d Te s ting and the Diagnosis of Latent Tuberculosis Infection and Tuberculosis Disease U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control
More informationDidactic Series. Latent TB Infection in HIV Infection
Didactic Series Latent TB Infection in HIV Infection Jacqueline Peterson Tulsky, MD UCSF Positive Health Program at SFGH Medical Director SF, North Coast and East Bay AETC January 8, 2015 ACCREDITATION
More informationRepeated tuberculin skin testing following therapy with TNF-alpha inhibitors
Clin Rheumatol (2009) 28:167 172 DOI 10.1007/s10067-008-1007-9 ORIGINAL ARTICLE Repeated tuberculin skin testing following therapy with TNF-alpha inhibitors Inbal Fuchs & Lone Avnon & Tamar Freud & Mahmoud
More information2016 OPAM Mid-Year Educational Conference, Sponsored by AOCOPM Sunday, March 13, 2016
Learning Objectives Tuberculosis Case Discussions: Evaluation for Tuberculosis Infection Melissa C. Overman, DO, MPH, CHES, FAOCOPM Describe appropriate technique for TST placement, reading and interpretation
More informationJennifer Lam MPH candidate 2009 Johns Hopkins Bloomberg School of Public Health. Preceptors: Wendy Cronin, PhD MT(ASCP), Cathy Goldsborough, RN
Jennifer Lam MPH candidate 2009 Johns Hopkins Bloomberg School of Public Health Preceptors: Wendy Cronin, PhD MT(ASCP), Cathy Goldsborough, RN Phase Symposium: May 6, 2009 Background & Rationale Maryland
More informationNew Approaches to the Diagnosis and Management of Tuberculosis Infection in Children and Adolescents
New Approaches to the Diagnosis and Management of Tuberculosis Infection in Children and Adolescents Jeffrey R. Starke, M.D. Professor of Pediatrics Baylor College of Medicine [With great thanks to Andrea
More informationABSTRACT. Original Article Respiratory Diseases
J Korean Med Sci. 2018 Nov 19;33(47):e292 eissn 1598-6357 pissn 1011-8934 Original Article Respiratory Diseases Incidence of Active Tuberculosis within One Year after Tumor Necrosis Factor Inhibitor Treatment
More informationPredictive Value of interferon-gamma release assays for incident active TB disease: A systematic review
Predictive Value of interferon-gamma release assays for incident active TB disease: A systematic review Lele Rangaka University of Cape Town, South Africa mxrangaka@yahoo.co.uk 1 The 3 I s Isoniazid preventive
More informationWhat the Primary Physician Should Know about Tuberculosis. Topics for Discussion. Global Impact of TB
What the Primary Physician Should Know about Tuberculosis Henry F. Chambers, M.D Professor of Medicine, UCSF Topics for Discussion Epidemiology Common disease presentations Diagnosis of active TB Screening
More informationTuberculosis Education for the Medical Professional
Tuberculosis Education for the Medical Professional North Dakota Diagnosis and Medical Management of Latent TB Infection Dawn Farrell, RN, BSN, PHN Maria Robles, BSN July 10, 2007 Tuberculosis Education
More informationAnnual Rheumatology & Therapeutics Review for Organizations & Societies
Annual Rheumatology & Therapeutics Review for Organizations & Societies Opportunistic Infections and Tuberculosis Risk Management Learning Objectives Define the risks of TB and non-tb opportunistic infections,
More informationTreat to a Target The New Paradigm in the Management of RA. Boulos Haraoui, MD FRCPC Université de Montréal Institut de rhumatologie de Montréal
Treat to a Target The New Paradigm in the Management of RA Boulos Haraoui, MD FRCPC Université de Montréal Institut de rhumatologie de Montréal Disclosure Dr Boulos Haraoui Advisor/Research Grants/Speakers
More information10/3/2017. Updates in Tuberculosis. Global Tuberculosis, WHO 2015 report. Objectives. Disclosures. I have nothing to disclose
Disclosures Updates in Tuberculosis I have nothing to disclose Chris Keh, MD Assistant Clinical Professor, Division of Infectious Diseases, UCSF TB Controller, TB Prevention and Control Program, Population
More informationWhat the Primary Physician Should Know about Tuberculosis. Topics for Discussion. Life Cycle of M. tuberculosis
What the Primary Physician Should Know about Tuberculosis Henry F. Chambers, M.D Professor of Medicine, UCSF Topics for Discussion Microbiology Epidemiology Common disease presentations Diagnosis of active
More informationPerioperative Medicine:
Perioperative Medicine: Management of rheumatologic agents Divya Gollapudi, MD May 2016 Medical Operative Consult Clinic Harborview Medical Center Your patient Ms. L is a 55 year-old F w/ h/o RA who presents
More information